UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 547

Sortiert nach

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

Annals of oncology, 2013-03, Vol.24 (3), p.640-647

2013

Volltextzugriff (PDF)

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

Annals of oncology, 2014-02, Vol.25 (2), p.339-345

2014

Volltextzugriff (PDF)

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients

British journal of cancer, 2013-12, Vol.109 (12), p.2959-2964

2013

Volltextzugriff (PDF)

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype

Annals of oncology, 2015-08, Vol.26 (8), p.1685-1691

2015

Volltextzugriff (PDF)

Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry

Breast (Edinburgh), 2022-08, Vol.64, p.127-133

2022

Volltextzugriff (PDF)

PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial

British journal of surgery, 2021-04, Vol.108 (3), p.308-314

2021

Volltextzugriff (PDF)

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial

British journal of cancer, 2015-04, Vol.112 (8), p.1405-1410

2015

Volltextzugriff (PDF)

Prognostic value of endopredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials

Annals of oncology, 2019-05, Vol.30, p.iii1-iii1

2019

Volltextzugriff (PDF)

Brain metastases free survival differs between breast cancer subtypes

British journal of cancer, 2012-01, Vol.106 (3), p.440-446

2012

Volltextzugriff (PDF)

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)

Annals of oncology, 2014-02, Vol.25 (2), p.366-371

2014

Volltextzugriff (PDF)

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases

British journal of cancer, 2012-01, Vol.106 (1), p.25-31

2012

Volltextzugriff (PDF)

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer

British journal of cancer, 2014-08, Vol.111 (5), p.837-842

2014

Volltextzugriff (PDF)

Prognostic impact of breast cancer subtypes in elderly patients

Breast cancer research and treatment, 2016-05, Vol.157 (1), p.91-99

2016

Volltextzugriff (PDF)

Utilization and performance of the Prosigna® breast cancer prognostic gene signature assay at the Medical University of Vienna

Annals of oncology, 2019-05, Vol.30, p.iii9-iii9

2019

Volltextzugriff (PDF)

mRNA expression of ER, PR, HER2 and Ki67 are concordant to central ihc and predict clinical outcome: A validation study from the ABCSG-6 biomarker cohort

Annals of oncology, 2018-10, Vol.29, p.viii480-viii480

2018

Volltextzugriff (PDF)

Androgen receptor expression in breast cancer brain metastases

Annals of oncology, 2018-10, Vol.29, p.viii124-viii124

2018

Volltextzugriff (PDF)

ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6

ESMO open, 2021-08, Vol.6 (4), p.100228-100228, Article 100228

2021

Volltextzugriff (PDF)

High resolution MRI of the breast at 3 T: which BI-RADS® descriptors are most strongly associated with the diagnosis of breast cancer?

European radiology, 2012-02, Vol.22 (2), p.322-330

2012

Volltextzugriff (PDF)

Intraoperative frozen section analysis for breast-conserving therapy in 1016 patients with breast cancer

European journal of surgical oncology, 2009-03, Vol.35 (3), p.264-270

2009

Volltextzugriff (PDF)

A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort

ESMO open, 2021-02, Vol.6 (1), p.100006-100006, Article 100006

2021

Volltextzugriff (PDF)

Intratumoral Cytokeratin 5 and Claudin 3 protein expression predicts for the presence of a BRCA1 germline mutation in women with early breast cancer

Breast (Edinburgh), 2017-03, Vol.32, p.S31-S31

2017

Volltextzugriff (PDF)

2923 Role of endocrine therapy in breast cancer (BC) patients with brain metastases

European journal of cancer (1990), 2015-09, Vol.51, p.S592-S592

2015

Volltextzugriff (PDF)

Histologic work-up of non-palpable breast lesions classified as probably benign at initial mammography and/or ultrasound (BI-RADS category 3)

European journal of radiology, 2013-03, Vol.82 (3), p.398-403

2013

Volltextzugriff (PDF)

Fulvestrant and male breast cancer: a case series

Annals of oncology, 2013-01, Vol.24 (1), p.265-266

2013

Volltextzugriff (PDF)

411 Agreement Between Visual and Automated Assessment of HER2 Overexpression and Ki67 Labeling Index in Breast Cancer–Comparison of Core Biopsy and Surgical Specimens

European journal of cancer (1990), 2012-03, Vol.48, p.S166-S166

2012

Volltextzugriff (PDF)

1 – 25 von 547

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(421)
Mit Volltextzugriff
(448)

Publikationsform

Sprache

7 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(330)
Humans
(204)
Life Sciences & Biomedicine
(199)
Female
(155)
Technology
(116)
Middle Aged
(110)
Adult
(108)
Biological And Medical Sciences
(98)
Aged
(95)
Medical Sciences
(91)
Male
(85)
Computer Science
(74)
Oncology
(73)
Computer Science, Artificial Intelligence
(68)
Engineering
(64)
Breast Neoplasms - Pathology
(58)
Tumors
(48)
Automation & Control Systems
(44)
Aged, 80 And Over
(40)
Engineering, Electrical & Electronic
(40)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype

Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry

PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial

Prognostic value of endopredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials

Brain metastases free survival differs between breast cancer subtypes

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer

Prognostic impact of breast cancer subtypes in elderly patients

Utilization and performance of the Prosigna® breast cancer prognostic gene signature assay at the Medical University of Vienna

mRNA expression of ER, PR, HER2 and Ki67 are concordant to central ihc and predict clinical outcome: A validation study from the ABCSG-6 biomarker cohort

Androgen receptor expression in breast cancer brain metastases

ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6

High resolution MRI of the breast at 3 T: which BI-RADS® descriptors are most strongly associated with the diagnosis of breast cancer?

Intraoperative frozen section analysis for breast-conserving therapy in 1016 patients with breast cancer

A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort

Intratumoral Cytokeratin 5 and Claudin 3 protein expression predicts for the presence of a BRCA1 germline mutation in women with early breast cancer

2923 Role of endocrine therapy in breast cancer (BC) patients with brain metastases

Histologic work-up of non-palpable breast lesions classified as probably benign at initial mammography and/or ultrasound (BI-RADS category 3)

Fulvestrant and male breast cancer: a case series

411 Agreement Between Visual and Automated Assessment of HER2 Overexpression and Ki67 Labeling Index in Breast Cancer–Comparison of Core Biopsy and Surgical Specimens

Suchergebnisse filtern